Back

Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Shizuya Yamashita

Rinku General Medical Center, Izumisano (Japan)

5 More presentations in this session

Presentation thumbnail
Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl
Doctor J. Nelson (Fresno, US)
Abstract Slides Video
Presentation thumbnail
Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations
Miss D. Dunca (London, GB)
Abstract Slides Video
Presentation thumbnail
RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys
Professor L. Gan (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation
Doctor L. Michael (Indianapolis, US)
Abstract Slides Video
Presentation thumbnail
Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome
Doctor A. Nakamura (Morioka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial
thumbnail
Congress Presentation
Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources